{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T20:08:55Z","timestamp":1793909335644,"version":"4.8.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:00:00Z","timestamp":1739836800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023280","name":"Seqirus Australia Pty Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023280","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.vaccine.2025.126883","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T01:12:03Z","timestamp":1739668323000},"page":"126883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models"],"prefix":"10.1016","volume":"51","author":[{"given":"Cheng","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsh","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Scalzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Petkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Rossignol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxia","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2025.126883_bb0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2025.126883_bb0010","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.vaccine.2025.126883_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.789427","article-title":"The critical contribution of Pseudouridine to mRNA COVID-19 vaccines","volume":"9","author":"Morais","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.vaccine.2025.126883_bb0020","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28164","article-title":"Vaccine-induced binding and neutralizing antibodies against omicron 6 months after a homologous BNT162b2 booster","volume":"95","author":"Favresse","year":"2023","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2025.126883_bb0025","first-page":"133","article-title":"Durability of immune responses to mRNA booster vaccination against COVID-19","author":"Arunachalam","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.vaccine.2025.126883_bb0030","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1099\/jgv.0.000249","article-title":"Alphavirus RNA synthesis and non-structural protein functions","volume":"96","author":"Rupp","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2025.126883_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.04.012","article-title":"Slow delivery immunization enhances HIV neutralizing antibody and germinal center responses via modulation of Immunodominance","volume":"177","author":"Cirelli","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.vaccine.2025.126883_bb0040","series-title":"9th European scientific working group on influenza conference. Valencia, Spain","article-title":"Self-amplifying mRNA SARS-CoV-2 vaccines elicit robust, cross-reactive and durable neutralizing booster responses in previously mRNA vaccinated adults","author":"Low","year":"2023"},{"key":"10.1016\/j.vaccine.2025.126883_bb0045","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.ymthe.2017.11.017","article-title":"Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses","volume":"26","author":"Vogel","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2025.126883_bb0050","series-title":"National Research Council Committee for the update of the guide for the care and use of laboratory animals. Guide for the care and use of laboratory animals","year":"2011"},{"key":"10.1016\/j.vaccine.2025.126883_bb0055","series-title":"Manual for the laboratory diagnosis and virological surveillance of influenza","author":"WHO Global Influenza Surveillance Network","year":"2011"},{"key":"10.1016\/j.vaccine.2025.126883_bb0065","doi-asserted-by":"crossref","first-page":"24075","DOI":"10.1073\/pnas.1908052116","article-title":"mRNA structure regulates protein expression through changes in functional half-life","volume":"116","author":"Mauger","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2025.126883_bb0070","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1021\/acscentsci.1c00197","article-title":"Modifications in an emergency: the role of N1-Methylpseudouridine in COVID-19 vaccines","volume":"7","author":"Nance","year":"2021","journal-title":"ACS Cent Sci"},{"key":"10.1016\/j.vaccine.2025.126883_bb0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S1473-3099(23)00650-3","article-title":"Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"24","author":"Oda","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2025.126883_bb0080","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s12276-023-01105-x","article-title":"CD8 T-cell subsets: heterogeneity, functions, and therapeutic potential","volume":"55","author":"Koh","year":"2023","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.vaccine.2025.126883_bb0085","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.126883_bb0090","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/s41586-022-05216-9","article-title":"Long-primed germinal centres with enduring affinity maturation and clonal migration","volume":"609","author":"Lee","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2025.126883_bb0095","first-page":"11","article-title":"Toxicological assessments of a pandemic COVID-19 vaccine-demonstrating the suitability of a platform approach for mRNA vaccines","author":"Rohde","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2025.126883_bb0100","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.ymthe.2022.01.001","article-title":"A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models","volume":"30","author":"Maruggi","year":"2022","journal-title":"Mol Ther"},{"key":"10.1016\/j.vaccine.2025.126883_bb0105","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2025.126883_bb0110","series-title":"Comparison of the immunogenicity of bivalent self-amplifying mRNA and mRNA vaccines against various SARS-CoV-2 variants up to six months postvaccination. OPTIONS XII. Brisbane","author":"Okada","year":"2024"},{"key":"10.1016\/j.vaccine.2025.126883_bb0115","unstructured":"Okada Y, Kumagai Y, Okura I, Ohtsuki M, Ishida N, Iwama Y, et al. Self-amplifying mRNA COVID-19 vaccine induces a superior immune response compared with mRNA vaccine that persists to 12 months postvaccination. OPTIONS XII. Brisbane 2024."},{"key":"10.1016\/j.vaccine.2025.126883_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(24)00060-4","article-title":"12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine","author":"Oda","year":"2024","journal-title":"Lancet Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500180X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2500180X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T21:39:12Z","timestamp":1745357952000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2500180X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":23,"alternative-id":["S0264410X2500180X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126883","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"sa-mRNA influenza vaccine raises a higher and more durable immune response than mRNA vaccine in preclinical models","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2025.126883","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 CSL Seqirus. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126883"}}